Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01565538

Recruitment Status : Completed

First Posted : March 28, 2012

Results First Posted : September 15, 2014

Last Update Posted : September 15, 2014

Sponsor:

Information provided by (Responsible Party):

Si-Yu Wang, Sun Yat-sen University

Study Description

Brief Summary:

Both pemetrexed and erlotinib are second-line treatment options for patients with advanced non-small cell lung cancer. It is controversial that whether it is necessary to detect epidermal growth factor receptor (EGFR) mutation status for the EGFR-targeted therapy after the failure of standard chemotherapy. The role of EGFR gene copy number as a predictive marker remains controversial. Therefore, we investigate the efficacy of erlotinib and pemetrexed as second-line therapy in treating in patients with EGFR wild-type and EGFR FISH-positive advanced lung adenocarcinoma.

Condition or disease	Intervention/treatment	Phase
Lung Cancer	Drug: Erlotinib Drug: Pemetrexed	Phase 2

Detailed Description:

Standard first-line treatment for advanced-stage non-small cell lung cancer (NSCLC) usually consists of platinum-based doublet chemotherapy, but progression ultimately occurs for most patients. Second-line treatment options available to patients who suffer failure of first-line treatment include further chemotherapy (docetaxel and pemetrexed) or targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show great efficacy in patients with advanced NSCLC with EGFR mutation. High EGFR gene copy number was associated with great sensitivity and prolonged progression-free survival of NSCLC from EGFR-TKIs. This phase II study was designed to assess the efficacy and safety of erlotinib compared with pemetrexed as second-line treatment for EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	123 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma
Study Start Date :	December 2008
Actual Primary Completion Date :	May 2012
Actual Study Completion Date :	May 2013

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Lung cancer

Drug Information available for: Pemetrexed Pemetrexed disodium Erlotinib hydrochloride Erlotinib

Genetic and Rare Diseases Information Center resources: Lung Adenocarcinoma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Erlotinib Erlotinib at the dose of 150 mg orally once a day continually until progression.	Drug: Erlotinib 150 mg Given orally Other Name: Tarceva
Experimental: Pemetrexed Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.	Drug: Pemetrexed 500mg/m2 Given IV Other Name: ALIMTA

Outcome Measures

Primary Outcome Measures :

Progression-Free Survival [ Time Frame: From the date of randomization to the date of tumour progression or death from any cause, assessed until at least 12 months after randomization. ]
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Secondary Outcome Measures :

Best Tumor Response [ Time Frame: From the date of randomization, assessed every 6 weeks, until at least 12 months after randomization. ]
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Overall Survival [ Time Frame: From date of randomization until the date of death from any cause, assessed until at least 12 months after randomization. ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histologically or cytologically confirmed Lung adenocarcinoma
Wld-type EGFR
Stage IIIB/IV
Failure to prior chemotherapy
Life expectancy of more than 3 months
Tissue sample desired for genomic study
Age ≥ 18 years
Performance status (WHO) < 3
Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9gr/mm^3)
Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function (creatinine < 2mg/dl)
Presence of two-dimensional measurable disease. The measurable disease should not have been irradiated
Informed consent

Exclusion Criteria:

Have previously received pemetrexed or TKIs
Other concurrent uncontrolled illness

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565538

Locations


China, Guangdong
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060

Sponsors and Collaborators

Si-Yu Wang

Investigators


Principal Investigator:	Si-Yu Wang, Doctor	Sun Yat-sen University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, Wang SY. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer. 2014 May 1;120(9):1379-86. doi: 10.1002/cncr.28591. Epub 2014 Jan 30.


Responsible Party:	Si-Yu Wang, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier:	NCT01565538 History of Changes
Other Study ID Numbers:	wsy001
First Posted:	March 28, 2012 Key Record Dates
Results First Posted:	September 15, 2014
Last Update Posted:	September 15, 2014
Last Verified:	September 2014

Keywords provided by Si-Yu Wang, Sun Yat-sen University:


Cancer Non-small-cell lung cancer Adenocarcinoma EGFR gene mutation	Chemotherapy Pemetrexed Erlotinib

Additional relevant MeSH terms:


Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Erlotinib Hydrochloride Pemetrexed	Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors

To Top